Fulcrum Therapeutics (FULC) PT Raised to $4.50 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts FULC Hot Sheet
Price: $3.71 -1.59%
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $4.50 (from $4.00) while maintaining a Underperform rating.
You May Also Be Interested In
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- Monolithic Power Systems (MPWR) PT Raised to $1,906 at Truist Securities
- Freedom Broker Downgrades RPC Inc. (RES) to Sell
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
